Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01140841 · ClinicalTrials.gov registry record
A Study of Safety and Tolerability of Fipamezole in Adult Subjects With Parkinson's Disease Who Are Receiving Levodopa
A clinical trial, sponsored by Bausch Health Americas.
- Completed
- Registry status
- 40
- Enrollment target
NCT01140841 is a clinical trial that has completed, run by Bausch Health Americas. The registered enrollment target is 40 participants.
The verdict
NCT01140841 has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to determine the maximum tolerated dose of Fipamezole in adult patients with Parkinson's disease who are receiving levodopa.
Interventions
- DRUG Placebo
- DRUG Fipamezole ODT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2010-06 |
| Est. Completion | 2010-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01140841
The ClinicalTrials.gov registry entry for NCT01140841 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01140841 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01140841 about?
NCT01140841 is a clinical study titled "A Study of Safety and Tolerability of Fipamezole in Adult Subjects With Parkinson's Disease Who Are Receiving Levodopa". The purpose of this clinical trial is to determine the maximum tolerated dose of Fipamezole in adult patients with Parkinson's disease who are receiving levodopa.
What is the current status of trial NCT01140841?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2010-06. Estimated completion is 2010-11.
What interventions are being tested in trial NCT01140841?
The interventions under investigation include: Placebo (DRUG), Fipamezole ODT (DRUG).
Who is sponsoring clinical trial NCT01140841?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.